Key takeaways
Mayzent (siponimod) and Glatiramer (Copaxone, Glatopa) are both used to treat relapsing forms of multiple sclerosis (MS), but they have some key differences. Mayzent is taken orally as a tablet once a day, while Glatiramer is injected under the skin either daily or three times a week. Mayzent requires genetic testing before starting treatment to determine the appropriate dose, whereas Glatiramer does not. Mayzent is only available as a brand-name medication, but Glatiramer is available in both brand-name and generic forms. Common side effects of Mayzent include headache, high blood pressure, and falls, while Glatiramer often causes injection site reactions like pain and swelling. Additionally, Mayzent is considered an immunosuppressant, which can increase your risk of infections, whereas Glatiramer is not classified as an immunosuppressant but can still affect your immune system.
